SCHEMBL4664563

SCHEMBL4664563

N#Cc1cc2c(Cl)ccnc2cc1OCCCN1CCCC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EHMT2 Q96KQ7 7/20 0.52
EHMT1 Q9H9B1 6/20 0.52
SRC P12931 8/20 0.50
ABL1 P00519 2/20 0.50
BCR P11274 2/20 0.50
MAP2K1 Q02750 2/20 0.47
IGF1R P08069 1/20 0.47
DNMT1 P26358 1/20 0.46
ALDH1A1 P00352 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HRH3 Q9Y5N1 2/20 0.45
FYN P06241 2/20 0.45
WEE2 P0C1S8 2/20 0.44
WEE1 P30291 2/20 0.44
PKMYT1 Q99640 2/20 0.44
STK25 O00506 1/20 0.44
CIT O14578 1/20 0.44
RIOK3 O14730 1/20 0.44
MAP2K7 O14733 1/20 0.44
CHEK1 O14757 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4664106 0.91 WEE2 (0.54) EHMT2EHMT1SRCABL1BCR
SCHEMBL6464138 0.90 SRC (0.57) SRCABL1BCRMAP2K1IGF1R
SCHEMBL4664567 0.89 SRC (0.45) EHMT2EHMT1SRCABL1BCR
SCHEMBL16707263 0.84 EHMT2 (0.56) EHMT2EHMT1SRCALDH1A1SMN1; SMN2
SCHEMBL29636829 0.82 EHMT2 (0.76) EHMT2EHMT1DNMT1EGFR
SCHEMBL8526894 0.82 EHMT2 (0.76) EHMT2EHMT1DNMT1EGFR
SCHEMBL2748129 0.81 EHMT2 (0.74) EHMT2EHMT1SRCABL1BCR
Hydrochloric Acid SCHEMBL6433786 0.81 EHMT2 (0.74) EHMT2EHMT1DNMT1EGFR
SCHEMBL4664598 0.81 SRC (0.54) EHMT2EHMT1SRCABL1BCR
SCHEMBL1893907 0.79 SRC (0.51) SRCABL1GAKEGFRERBB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080312273-A1 Quinoline Derivatives Having Vegf Inhibiting Activity HENNEQUIN LAURENT FRANCOIS ANDRE 2008-12-18 US disclosed
US-20080312273-A1 Quinoline Derivatives Having Vegf Inhibiting Activity HENNEQUIN LAURENT FRANCOIS ANDRE 2008-12-18 US disclosed
US-20080312273-A1 Quinoline Derivatives Having Vegf Inhibiting Activity HENNEQUIN LAURENT FRANCOIS ANDRE 2008-12-18 US disclosed
US-7371765-B2 Quinoline derivatives having VEGF inhibiting activity ASTRAZENECA AB (SE) 2008-05-13 US disclosed
US-7371765-B2 Quinoline derivatives having VEGF inhibiting activity ASTRAZENECA AB (SE) 2008-05-13 US disclosed
US-7371765-B2 Quinoline derivatives having VEGF inhibiting activity ASTRAZENECA AB (SE) 2008-05-13 US disclosed
US-20030199491-A1 Quinoline derivatives having vegf inhibiting activity ASTRAZENECA AB (SE) 2003-10-23 US disclosed
EP-1313726-A1 QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY AstraZeneca AB (SE) 2003-05-28 EP disclosed
WO-2002012226-A1 QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY ASTRAZENECA AB (SE) 2002-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312273-A1 Quinoline Derivatives Having Vegf Inhibiting Activity VEGFA, FLT1, FLT4 EHMT2 3654/4885EHMT1 2990/4885SRC 1933/4885
US-20030199491-A1 Quinoline derivatives having vegf inhibiting activity VEGFA, FLT1, FLT4 EHMT2 4385/4885EHMT1 3667/4885SRC 3356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.